Nonadherence to treatment protocol in published randomised controlled trials: a review

Trials

Volumn 13, Issue , 2012, Pages

  Dodd, Susanna ^a   White, Ian R ^b   Williamson, Paula ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Causal effect modelling; non compliance; nonadherence; trial analysis; trial reporting

Indexed keywords

HUMAN; INTENTION TO TREAT ANALYSIS; INTERVENTION STUDY; LONG TERM CARE; LONGITUDINAL STUDY; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SHORT COURSE THERAPY; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT REFUSAL;

HUMANS; MEDICATION ADHERENCE; PUBLISHING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84862266862     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-13-84     Document Type: Review

References (50)

1. World Health Organisation Adherence to Long-term Therapies: Evidence for Action 2003, World Health Organisation, Geneva, World Health Organisation.
2. Jin J, Sklar GE, Oh VMS, Li SC. Factors affecting therapeutic compliance: a review from the patient's perspective. Ther Clin Risk Manag 2008, 4:269-286. 2503662, 18728716.
3. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment. JAMA 2002, 288:2880-2883. 10.1001/jama.288.22.2880, 12472330.
4. Donovan J. Patient decision making: the missing ingredient in compliance research. Int J Technol Assess Health Care 1995, 11:443-455. 10.1017/S0266462300008667, 7591546.
5. DerSimonian R, Charette LJ, McPeek B, Mosteller F. Reporting on methods in clinical trials. N Eng J Med 1982, 306:1332-1337.
6. Freiman JA, Chalmers TC, Smith H, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. N Eng J Med 1978, 299:690-694.
7. Gøtzsche PC. Multiple publication of reports of drug trials. Eur J Clin Pharmacol 1989, 36:429-432. 10.1007/BF00558064, 2666138.
8. Gøtzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Control Clin Trials 1989, 10:31-56. 10.1016/0197-2456(89)90017-2, 2702836.
9. Meinert CL, Tonascia S, Higgins K. Content of reports on clinical trials: a critical review. Control Clin Trials 1984, 5:328-347. 10.1016/S0197-2456(84)80013-6, 6394208.
10. Mosteller F. Problems of omission in communications. Clin Pharmacol Ther 1979, 25:761-764.
11. Reiffenstein RJ, Schiltroth AJ, Todd DM. Current standards in reported drug trials. CMAJ 1968, 99:1134-1135.
12. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T, Consort G. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001, 134:663-694.
13. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010, 340:c869. 10.1136/bmj.c869, 2844943, 20332511.
14. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials. JAMA 1996, 276:637-639. 10.1001/jama.1996.03540080059030, 8773637.
15. Toerien M, Brookes ST, Metcalfe C, de Salis I, Tomlin Z, Peters TJ, Sterne J, Donovan JL. A review of reporting of participant recruitment and retention in RCTs in six major journals. Trials 2009, 10:52. 10.1186/1745-6215-10-52, 2717957, 19591685.
16. International Conference on Harmonisation E9 Expert Working Group ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. Stat Med 1999, 18:1905-1942. International Conference on Harmonisation E9 Expert Working Group.
17. White IR. Uses and limitations of randomization-based efficacy estimators. Stat Methods Med Res 2005, 14:327-347. 10.1191/0962280205sm406oa, 16178136.
18. Sheiner LB, Rubin DB. Intention-to-treat analysis and the goals of clinical trials. Clin Pharmacol Ther 1995, 57:6-15. 10.1016/0009-9236(95)90260-0, 7828382.
19. Nagelkerke N, Fidler V, Bernsen R, Borgdorff M. Estimating treatment effects in randomized clinical trials in the presence of non-compliance. Stat Med 2000, 19:1849-1864. 10.1002/1097-0258(20000730)19:14<1849::AID-SIM506>3.0.CO;2-1, 10867675.
20. Lewis JA, Machin D. Intention to treat - who should use ITT?. Br J Cancer 1993, 68:647-650. 10.1038/bjc.1993.402, 1968589, 8398686.
21. Sommer A, Zeger SL. On estimating efficacy from clinical trials. Stat Med 1991, 10:45-52. 10.1002/sim.4780100110, 2006355.
22. Bellamy SL, Lin JY, Have TRT. An introduction to causal modeling in clinical trials. Clin Trials 2007, 4:58-73. 10.1177/1740774506075549, 17327246.
23. Little RJ, Rubin DB. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health 2000, 21:121-145. 10.1146/annurev.publhealth.21.1.121, 10884949.
24. Greenland S, Lanes S, Jara M. Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and G-estimation. Clin Trials 2008, 5:5-13. 10.1177/1740774507087703, 18283074.
25. Vrijens B, De Geest S, Hughes DA, Kardas P, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C, Clyne W, Aronson JK, Urquhart J, . ABC Project Team A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 2011, 73:691-705. ABC Project Team.
26. Osterberg L, Blaschke T. Adherence to medication. N Eng J Med 2005, 353:487-497.
27. Vrijens B, Urquhart J. Patient adherence to prescribed antimicrobial drug dosing regimens. J Antimicrob Chemother 2005, 55:616-627. 10.1093/jac/dki066, 15772145.
28. Serebruany V, Oshrine B, Alex I, Atar D, Michelson A, Ferguson JJ. Noncompliance in cardiovascular clinical trials. Am Heart J 2005, 150:882-886. 10.1016/j.ahj.2005.02.039, 16290953.
29. Haynes RB, Dantes R. Patient compliance and the conduct and interpretation of therapeutic trials. Control Clin Trials 1987, 8:12-19. 10.1016/0197-2456(87)90021-3, 3568692.
30. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH, . Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Eng J Med 2005, 352:225-237. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators: .
31. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F-J, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, . TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Eng J Med 2007, 357:2001-2015. TRITON-TIMI 38 Investigators.
32. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002, 288:321-333. 10.1001/jama.288.3.321, 12117397, Writing Group for the Women's Health Initiative Investigators.
33. Reid IR, Mason B, Horne A, Ames R, Reid HE, Bava U, Bolland MJ, Gamble GD. Randomized controlled trial of calcium in healthy older women. Am J Med 2006, 119:777-785. 10.1016/j.amjmed.2006.02.038, 16945613.
34. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology 2005, 64:94-101. 10.1212/01.WNL.0000148604.77591.67, 15642910.
35. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SAA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML, . WHI Investigators Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008, 299:1036-1045. 10.1001/jama.299.9.1036, 18319414, WHI Investigators.
36. Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 2000, 56:779-788. 10.1111/j.0006-341X.2000.00779.x, 10985216.
37. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D, . VASST Investigators Vasopressin versus norepinephrine infusion in patients with septic shock. N Eng J Med 2008, 358:877-887. VASST Investigators.
38. Fergusson D, Aaron SD, Guyatt G, Hebert P. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ 2002, 325:652-654. 10.1136/bmj.325.7365.652, 1124168, 12242181.
39. Gravel J, Opatrny L, Shapiro S. The intention-to-treat approach in randomized controlled trials: are authors saying what they do and doing what they say?. Clin Trials 2007, 4:350-356. 10.1177/1740774507081223, 17848496.
40. Herman A, Botser IB, Tenenbaum S, Chechick A. Intention-to-treat analysis and accounting for missing data in orthopaedic randomized clinical trials. J Bone Joint Surg Am 2009, 91:2137-2143. 10.2106/JBJS.H.01481, 19723990.
41. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999, 319:670-674. 10.1136/bmj.319.7211.670, 28218, 10480822.
42. Kruse RL, Alper BS, Reust C, Stevermer JJ, Shannon S, Williams RH. Intention-to-treat analysis: who is in? Who is out?. J Fam Pract 2002, 51:969-971.
43. Gillings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Inf J 1991, 25:411-424.
44. Ioannidis JPA, Evans SJW, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D, . CONSORT Group Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004, 141:781-788. CONSORT Group.
45. White IR, Goetghebeur EJT. Clinical trials comparing two treatment policies: which aspects of the treatment policies make a difference?. Stat Med 1998, 17:319-339. 10.1002/(SICI)1097-0258(19980215)17:3<319::AID-SIM765>3.0.CO;2-F, 9493257.
46. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials?. Stat Med 1984, 3:409-420. 10.1002/sim.4780030421, 6528136.
47. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, . RECORD-1 Study Group Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456. 10.1016/S0140-6736(08)61039-9, 18653228, RECORD-1 Study Group.
48. National Institute for Health and Clinical Excellence Sunitinib for the treatment of gastrointestinal stromal tumours 2009, National Institute for Health and Clinical Excellence, London, National Institute for Health and Clinical Excellence.
49. National Institute for Health and Clinical Excellence Everolimus for the second-line treatment of advanced renal cell carcinoma 2010, National Institute for Health and Clinical Excellence, London, National Institute for Health and Clinical Excellence.
50. National Institute for Health and Clinical Excellence Pazopanib for the first-line treatment of advanced renal cell carcinoma 2011, National Institute for Health and Clinical Excellence, London, National Institute for Health and Clinical Excellence.